NCT04659603: SAR408701 in Patients With CEACAM5-positive Advanced Solid Tumors

Breast Cancer Type: HER2+, HR+ & HER2-negative, Triple Negative
Hormone Mutations: ER+, PR+
Other Mutations: CEACAM
Breast Cancer Tissue: 
Recruitment Status: Recruiting
Phase 2
Drug Category: Therapeutic Antibody

Key Eligibility Criteria:

Gender: All
Age: 18 Years and older (Adult, Older Adult)
Location of Metastases: 
Additional Notes: Patients must have tumors that express CEACAM 5 by centrally assessed IHC assay; Breast cancer patients are eligible for cohort A; Patents must have received at least 2 prior cytotoxic chemotherapy regimens for non-TNBC tumor type or at least 1 for TNBC tumor type, but not more than 4 in the locally recurrent or metastatic setting
Exclusions: Patients with untreated brain metastases or history of leptomeningeal disease; Patients using contact lenses who are not willing to stop wearing them for the duration of the study intervention; Patients with prior therapy targeting CEACAM5; Patients with prior maytansinoid DM4 treatment (e.g. including antibody-drug conjugates like anetumab ravtansine or mirvetuximab soravtansine)

Up ↑